Investing.com - Nabriva Therapeutics reported on Thursday second quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Nabriva Therapeutics announced earnings per share of $-0.3 on revenue of $525K. Analysts polled by Investing.com anticipated EPS of $-0.16 on revenue of $400K.
Nabriva Therapeutics shares are down 38.64% from the beginning of the year and are trading at $0.810 , down-from-52-week-high.They are under-performing the Nasdaq which is up 23.8% from the start of the year.
Nabriva Therapeutics follows other major Healthcare sector earnings this month
Nabriva Therapeutics's report follows an earnings beat by J&J on July 16, who reported EPS of $1.67 on revenue of $18.34B, compared to forecasts EPS of $1.49 on revenue of $17.61B.
Roche Holding ADR had beat expectations on July 23 with second quarter EPS of $1.45 on revenue of $15.27B, compared to forecast for EPS of $1.42 on revenue of $15.43B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar